Join Vera Therapeutics for a hybrid R&D day, featuring Richard Lafayette, MD, FACP, from Stanford University Medical Center, who will join company management to present Phase 2b eGFR and proteinuria data from week 72 of the ORIGIN Phase 2b clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), and Jonathan Barratt, PhD, FRCP, from the University of Leicester for a discussion of the results.

A live question and answer session will follow the formal presentation.